VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
14.9.2020 18:40:00 EEST | Business Wire | Press release
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, has announced that it has obtained an American and European patent for TOTUM-070, its active substance dedicated to reducing LDL-cholesterol in the blood (“bad cholesterol”).
TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63). The patent has been granted for the United States, Europe and South Africa.
TOTUM-070 targets excess LDL-cholesterol, which is a well-known risk factor for cardiovascular disease and the main cause of atherosclerosis1. It is believed that over 174 million adults in the US and Europe will suffer from hypercholesterolemia in 2020. The market for non-prescription products is estimated at €1.2 billion in these regions2.
Sébastien Peltier, CEO of VALBIOTIS, said: “With TOTUM-070, we are targeting a major market, one in which we stand out for our specific plant know-how, a high level of clinical evidence and robust intellectual property worldwide. This strategy has already borne fruit, with a major partnership aiming at developping and marketing our first active substance, TOTUM-63. Obtaining this patent for TOTUM-070 in regions where populations are particularly affected by hypercholesterolemia marks a milestone in our development model aimed at building new partnerships of this scale.”
The TOTUM-070 patent covers a wide range of food and pharmaceutical applications relating to lipid metabolism disorders, for example dyslipidemia, cholesterol and triglycerides. It is the focus of an international filing strategy reaching beyond the United States and Europe.
A Phase II clinical study evaluating the efficacy of TOTUM-070 in people with untreated moderate hypercholesterolemia will be launched before the end of the year. The initiation of this study will be communicated subsequently.
The objective for VALBIOTIS is to obtain the first proprietary health claim for reducing LDL-cholesterol, notably in Europe and North America, for a product containing neither phytosterols nor red yeast rice.
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R20-018), these documents being available on the Company’s website (www.valbiotis.com).
1 2018 Guideline on the Management of Blood Cholesterol, a report from the American College of Cardiology / American Heart Association, Journal Of The American College Of Cardiology, 2019.
2 AEC Partners data for the United States and VALBIOTIS’ 5 priority European countries (Germany, Spain, France, Italy and the United Kingdom), 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005535/en/
Contact information
CORPORATE COMMUNICATION / VALBIOTIS
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
media@valbiotis.com
FINANCIAL COMMUNICATION / ACTIFIN
Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CapVest Completes Majority Acquisition of Stada31.3.2026 14:10:00 EEST | Press release
CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty Pharmaceuticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331987319/en/ Building on strong 2025 results, the completion of the transaction will allow the CapVest and STADA teams to jointly progress their ambitious plans to accelerate the growth of the company globally and deploying capital towards pursuing organic growth and new strategic acquisitions. Currently employing close to 12,000 people worldwide, STADA is a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. The Company recently announced record revenues of €4.3 billion, a 6% incr
Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code31.3.2026 14:00:00 EEST | Press release
Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need. This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay. Softr’s new platform was built to bridge the gap between AI-generated prototypes and software that can actually run business operations. Many AI app builders promise instant
GetVocal Introduces Control Center to Help Enterprises Scale AI Across 90 Percent Plus of Customer Conversations31.3.2026 14:00:00 EEST | Press release
GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the launch of its Control Center, a human-AI operations interface designed to help enterprises scale customer experience (CX) automation while maintaining trust, compliance, and full human oversight. As organizations expand AI from simple requests to complex customer journeys, they face a dual operational challenge: if AI acts alone, risk increases; but if humans review everything, automation doesn’t scale. GetVocal’s Control Center solves this challenge by introducing a governance layer for real-time two-way human-AI collaboration. In this hybrid workforce model, AI resolves most customer interactions independently, and humans step in only when judgment, validation, or exception handling is required. The Control Center is the only solution that enables supervisors and operators to oversee, control, and collaborate with AI agents in real time. Human operators work alongside
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform31.3.2026 13:00:00 EEST | Press release
WHOOP, the human performance company, today announced it has raised $575 million in Series G funding at a $10.1 billion valuation, advancing its global expansion and long-term vision for personalized health. The round was led by Collaborative Fund and includes global participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Macquarie Capital (entities administered by Macquarie Capital), Glade Brook, B-Flexion, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures, and Bullhound Capital alongside a group of prominent global athletes and individual investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331399622/en/ WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform Individual investors in the round include Cristiano Ronaldo, LeBron James, Rory McIlroy, Reggie Miller, Niall Horan, Karen Wazen, Virgil van Dijk, Mathie
CORRECTING and REPLACING Lenovo Announces Global Partnership With David Beckham31.3.2026 12:28:00 EEST | Press release
Last paragraph before boilerplate should read: “David is not only a global figure across football, business, and culture, but is someone who understands the power of innovation to transform the world. That makes him the perfect partner to help us demonstrate how Smarter AI can drive better life and more efficient work for all." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330443523/en/ Lenovo Announces Global Partnership With David Beckham The updated release reads: LENOVO ANNOUNCES GLOBAL PARTNERSHIP WITH DAVID BECKHAM Lenovo today announced a global partnership with David Beckham, bringing together one of the world’s most recognized cultural figures and one of the world’s leading technology companies. The collaboration builds on Lenovo’s expanding role in global football, including its position as the Official Technology Partner of FIFA World Cup 2026™ and the FIFA Women’s World Cup 2027™. This first of its kind Lenov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom